No. of Printed Pages : 8 ER20-21T Q.

7 An antibiotic drug will be effective against which of the

Roll No. .................. following disease
a) Dengue b) Influenza
2nd Year / Pharmacy. c) Cholera d) Hepatitis
Subject : Pharmacology Q.8 The liver is the major organ for _______ of drugs
Time : 3 Hrs. M.M. : 80 a) Absorption b) Distribution
SECTION-A c) Metabolism d) Excretion
Note: Multiple choice questions. All questions are compulsory Q.9 The substances produced by or derived from living
(20x1=20) organisms that are used to kill bacteria or prevent their
Q.1 Who is the father of medicine ? multiplication is called__________.
a) Hippocrates b) Galen a) Antibiotics b) Hormones
c) Berg d) Landsteiner c) Antidotes d) Enzymes
Q.2 The major side effect of chloramphenicol is ? Q.10 Drugs are excreted from the body through _______
a) Nausea a) Kidney b) Intestines
b) Bone Marrow Depression c) Sweat d) All of the above
c) Vomiting
Q.11 Nitroglycerine is administered by which route ?
d) Headache
Q.3 Eno, Gelusil, Digene are which type of drugs? a) By parenteral route b) By sublingual route
a) Anti-histamines b) Anti-depressants c) By inhalation d) By insertion
c) Antacids d) Diuretics Q.12 Drugs used to destroy and expel worms are known
Q.4 Example of anti-emetic drugs as_______.
a) Ondansetron a) Antibiotics b) Anti-inflammatory
b) Propanolol c) Anti-helminthics d) Anti-pruritics
c) Hydrochlorthalidone Q.13 Drugs which dilate the blood vessels and used to lower
d) Salbutamol blood pressure are known as ________.
Q.5 Which anti-epileptic drug is administered by intranasal a) Vasodilators b) Vasoconstrictors
route ? c) Mydriatics d) Myotics
a) Midazolam b) Diazepam
Q.14 Which route of drug administration will be preferred for an
c) Clobazam d) Nitrazepam
Q.6 Which of the following is also known as Emergency unconscious patient ?
Hormone ? a) Oral ingestion b) Inhalation
a) Cortisol b) Adrenaline c) Enteral d) Intravenous
c) Prolactin d) ADH
(1) ER20-21T (2) ER20-21T
Q.15 5% Glucose Saline means __________. Q.25 Briefly explain therapeutic treatment of shock.
a) Each 100 ml contains 5gm glucose and 5gm Q.26 Describe the pharmacological action and contraindications of
sodium chloride streptokinase.
b) Each 100 ml contains 5gm glucose and 0.9gm Q.27 Define Bronchodilators and mention any two such drugs.
sodium chloride Q.28 What is the best medicine to treat stomach ulcers. Mention
c) Each 100 ml contains 5gm glucose and 0.4gm any two drugs belonging to this class.
sodium chloride Q.29 Briefly describe the drug Quinine.
d) Each 100 ml contains 0.5gm glucose and 0.9gm Q.30 Briefly describe the pharmacology of penicillin.
sodium chloride Q.31 Write a short note on Autocoids.
Q.16 An agent used to increase the level of haemoglobin content in SECTION-C
the blood is known as __________. Note: Long answer type question. Attempt any six questions.
a) Hematinic b) Hemostatic (6x5=30)
c) Oxytocic d) Diuretic Q.32 Define and classify sulfonamides. Briefly describe the
Q.17 The largest herbarium of the world is located in ________. Pharmacology of these drugs with two suitable example.
a) Royal Botanical Garden, Kew Q.33 Define and classify Opioid Analgesics. Describe the
b) Central National Herbarium, Shibpur pharmacology & contraindications with a suitable example.
c) Museum of Natural History, Paris Q.34 Describe in detail the physiological & pathological role and
d) Madras Herbarium, Coimbatore clinical uses of Insulin.
Q.18 Which of the following is a Selective Serotonin Reuptake Q.35 Describe in detail the advantages and disadvantages
Inhibitor ? associated with parenteral Route of Administration.
a) Selegiline b) Fluoxetine Q.36 Define and classify Cholinergic drugs Elaborate the
c) Bupropion d) Doxepin
pharmaological action and cintraindications of any one
Q.19 Which of the following is an anti-anginal drug ?
a) Diltiazem b) Propranolol cholinergic drug.
c) Nitroglycerin d) All of the above Q.37 Describe pharmacological action of any two.
Q.20 Which of the following is not an aminoglycoside antibiotic? a) Anti-Hypertensive Drugs
a) Steptomycin b) Neomycin b) Anti-Neoplastic drugs
c) Kanamycin d) Cephalexin c) Anti-Fungal Drugs
SECTION-B d) Estrogens
Note: Short answer type question. Attempt any ten questions out of Q.38 Define and classify anti-tubercular drugs. Describe
Eleven questions. (10x3=30) briefly about any one anti-tubercular drug.
Q.21 Define bioavailability and factors infuencing bioavailability.
Q.22 Write a brief note on pilocarpine.
Q.23 Write a short note on an Anti-depressant drug
Q.24 Briefly describe the drug paracetamol.
(3) (2260) (4) ER20-21T
ER20-21T
 No. of Printed Pages : 8 ER20-21T ç-7 ,d ,aVhck;ksfVd nok fuEufyf•r esa ls fdl jksx ds f•ykiQ çHkkoh
Roll No. .................. gksxh\
d) Msaxw [k) bUÝyw,atk
2nd Year / Pharmacy x) gStk ?k) gsisVkbfVl
Subject : Pharmacology
ç-8 ;Ñr (liver) nokvksa ds _______ ds fy, çeq• vax gSA
Time : 3 Hrs. M.M. : 80 d) vo'kks"k.k (Absorption) [k) forj.k (Distribution)
Hkkx & d x) esVkcksfyt~e (Metabolism) ?k) mRltZu (Excretion)
uksV%& cgq fodYih; ç'uA lHkh ç'u vfuok;Z gSaA (20x1=20) ç-9 os inkFkZ tks thfor thoksa }kjk mRikfnr ;k fudkys tkrs gSa] vkSj ftUgsa
cSDVhfj;k dks ekjus ;k muds o`f¼ dks jksdus ds fy, mi;ksx fd;k tkrk
ç-1 fpfdRlk ds firk dkSu gSa\
gS] mUgsa _______ dgk tkrk gSA
d) fgIiksØsV~l [k) xSyu d) ,aVhck;ksfVDl [k) gkekZsu
x) cxZ ?k) ySaMLVhuj x) çfrfo"k (Antidotes) ?k) ,atkbe
ç-2 DyksjkEiQsuhdksy dk çeq• nq"çHkko D;k gS\ ç-10 nok,a 'kjhj ls _______ ds ekè;e ls mRlftZr gksrh gSaA
d) mYVh [k) cksu eSjks volkn (Bone Marrow Depression) d) xqnZs (Kidney) [k) vkar (Intestines)
x) eryh ?k) fljnnZ x) ilhuk (Sweat) ?k) mijksDr lHkh
ç-3 bZuks] tsY;qfly] Mkbftu fdl çdkj dh nokb;k¡ gSa\ ç-11 ukbVªksfXyljhu fdl ekxZ }kjk nh tkrh gS\
d) ,aVh&fgLVkfeUl [k) ,aVh&fMçslsaV~l d) iSjsaVsjy ekxZ (Parenteral route)
[k) lcfyaxqvy ekxZ (Sublingual route)
x) ,aVkflM~l ?k) ew=ko/Zd x) 'olu (Inhalation)
ç-4 ,aVh&,esfVd (anti-emetic) nokb;ksa dk mnkgj.k dkSu lh gS\ ?k) bUl'kZu (Insertion)
d) vksUMslsVªksu [k) çksçkuksyksy ç-12 og nok,¡ tks Ñfe;ksa (worms) dks u"V djus vkSj ckgj fudkyus ds
x) gkbMªksDyksjksfFk;kMksu ?k) lkYcqVkeksy fy, mi;ksx dh tkrh gSa] mUgsa _______ dgk tkrk gSA
ç-5 dkSu lh ,aVh&,fiysfIVd nok ukd ds ekxZ }kjk nh tkrh gS\ d) ,aVhck;ksfVDl [k) ,aVh&bUÝysesVjh
x) ,aVh&gsfYeafFkDl ?k) ,aVh&çqfjfVDl
d) feMktksye [k) Mk;tsike
x) Dyksckte ?k) ukbVªktsike
ç-13 os nok,¡ tks jDr okfgdkvksa dks foLrkfjr djrh gSa vkSj jDrpki dks de
djus ds fy, mi;ksx dh tkrh gSa] mUgsa _______ dgk tkrk gSA
ç-6 fuEufyf•r esa ls dkSu lk ^vkikrdkyhu gkekZsu* ds :i esa Hkh tkuk d) oklksfMysVlZ (Vasodilators)
tkrk gS\ [k) oklksdfULVªDVlZ (Vasoconstrictors)
d) dksfVZlksy [k) ,Mªsukfyu x) ekbfMª;kfVDl (Mydriatics)
x) çksySfDVu ?k) ADH (,aVh&Mk;;wjsfVd gkekZsu) ?k) E;kskfVDl (Myotics)
(5) ER20-21T (6) ER20-21T
ç-14 fdl ekxZ }kjk nok nh tkuh pkfg, tc jksxh csgks'k gks\ iz-23 ,d ,aVh&fMçslsaV (Anti&depressant) nok ij laf{kIr uksV fy•saA
d) ekSf•d lsou (Oral ingestion) [k) 'olu (Inhalation) iz-24 iSjkflVkeksy (Paracetamol) nok dk laf{kIr fooj.k nsaA
x) vkarfjd (Enteral) ?k) var%f'kjk (Intravenous) iz-25 'kkWd (Shock) ds mipkj dh fpfdRlh; fof/ dks la{ksi esa le>k,aA
iz-26 LVªsIVksfdust (Streptokinase) ds vkS"k/h; fØ;k vkSj contraindications
ç-15 5» Xywdkst lykbu dk eryc gS __________A dk o.kZu djsaA
d) çR;sd 100 fe-yh- esa 5 xzke Xywdkst vkSj 5 xzke lksfM;e DyksjkbM iz-27 czksUdksMk;ysVlZ (Bronchodilators) dh ifjHkk"kk nsa vkSj ,sls nks nokvksa
[k) çR;sd 100 fe-yh- esa 5 xzke Xywdkst vkSj 0-9 xzke lksfM;e DyksjkbM dk mYys• djsaA
x) çR;sd 100 fe-yh- esa 5 xzke Xywdkst vkSj 0-4 xzke lksfM;e DyksjkbM iz-28 isV ds vYlj (Stomach ulcers) dk bykt djus ds fy, lcls vPNh
?k) çR;sd 100 fe-yh- esa 0-5 xzke Xywdkst vkSj 0-9 xzke lksfM;e DyksjkbM
nok dkSu lh gS\ bl Js.kh esa vkus okyh nks nokvksa dk mYys• djsaA
ç- 16 ,d ,tsaV ftldk mi;ksx jDr esa gheksXyksfcu dh ek=kk c<+kus ds fy, iz-29 fDofuu (Quinine) nok dk laf{kIr fooj.k nsaA
fd;k tkrk gS] mls __________ dgk tkrk gSA iz-30 isfuflfyu (Penicillin) dh vkS"k/h; fØ;k dk laf{kIr o.kZu djsaA
d) ghesfVfud [k) gheksLVSfVd iz-31 vkWVksdksbM~l (Autocoids) ij laf{kIr uksV fy•saA
x) vkWDlhVksfld ?k) ew=ko/Zd Hkkx & x
ç- 17 nqfu;k dk lcls cM+k gcZsfj;e dgk¡ fLFkr gS\ uksV%& nh?kZ mÙkjh; ç'uA 7 esa ls fdUgha 6 ç'uksa dks gy dhft,A (6x5=30)
d) jkW;y cksVSfudy xkMZu] D;w iz-32 lYiQksukekbM~l (Sulfonamides) dh ifjHkk"kk nsa vkSj budk oxhZdj.k
djsaA bu nokvksa dh vkS"k/ foKku dk laf{kIr fooj.k nsa vkSj nks mi;qDr
[k) dsaæh; jk"Vªh; gcZsfj;e] f'kciqj mnkgj.kksa ds lkFk bls le>k,aA
x) E;wft;e vkWiQ uspqjy fgLVªh] isfjl iz-33 vksfivksbM ,usYtsflDl (Opioid Analgesics) dh ifjHkk"kk nsa vkSj budk
?k) eækl gcZsfj;e] dks;acVwj oxhZdj.k djsaA bu nokvksa dh vkS"k/ foKku vkSj foifjr ladsrks dk o.kZu djsa
ç- 18 fuEufyf•r esa ls dkSu lk p;ukRed lsjksVksfuu jhiVsd bufgfcVj (SSRI) gS\ vkSj ,d mi;qDr mnkgj.k ds lkFk bls le>k,aA
d) lsysfxykbu [k) ÝyqvksDlsVhu iz-34 balqfyu (Insulin) dh 'kkjhfjd vkSj jksxkRed Hkwfedk] vkSj blds fpfdRlh;
x) cqçkWfi;u ?k) MksDlsfiu mi;ksxksa dk foLrkj ls o.kZu djsaA
iz-35 iSr`d ç'kklu ekxZ (Parenteral Route of Administration) ds
ç- 19 fuEufyf•r esa ls dkSu lk ,aVh&,atkbuk (anti-anginal) nok gS\ iQk;ns vkSj uqdlku dk foLrkj ls o.kZu djsaA
d) fMYVk;tse [k) çksçkuksyksy iz-36 dksfyuftZd nokvksa (Cholinergic Drugs) dh ifjHkk"kk nsa vkSj budk
x) ukbVªksfXyljhu ?k) mijksDr lHkh oxhZdj.k djsaA fdlh ,d dksfyuftZd nok dh vkS"k/ fØ;k vkSj foifjr
ç- 20 fuEufyf•r esa ls dkSu lk ,d ,ehuksXykbdkslkbM ,aVhck;ksfVd ugha gS\ ladsr dk foLrkj ls o.kZu djsaA
d) LVªsIVksekbflu [k) fu;ksekbflu iz-37 fuEufyf•r esa ls fdlh nks dh vkS"k/ fØ;k dk fooj.k nsa%
d) ,aVh&gkbijVsa'ku nok,¡ (Anti&Hypertensive Drugs)
c) dkukekbflu ?k) lsiQkysfDlu [k) ,aVh&uhvksIykfLVd nok,¡ (Anti&Neoplastic Drugs)
Hkkx & [k x) ,aVh&iQaxy nok,¡ (Anti&Fungal Drugs)
uksV%& y?kq mÙkjh; ç'uA 11 esa ls fdUgha 10 ç'uksa dks gy dhft,A ?k) ,LVªkstsUl (Estrogens)
(10x3=30) iz-38 ,aVh&VÔwcjdqyj nokvksa (Anti&Tubercular Drugs) dh ifjHkk"kk nsa vkSj
iz-21 tSo miyC/rk (Bioavailability) dh ifjHkk"kk nsa vkSj tSo miyC/rk dks budk oxhZdj.k djsaA fdlh ,d ,aVh&VÔwcjdqyj nok ds ckjs esa laf{kIr
çHkkfor djus okys dkjdksa dk o.kZu djsaA fooj.k nsaA
iz-22 fiyksdkjfiu (Pilocarpine) ij laf{kIr uksV fy•saA

(7) ER20-21T (2260) (8) ER20-21T

 No. of Printed Pages : 8 ER20-22T Q.6 What does the abbreviation ‘O.D.’ written on a
Roll No. .................. prescription mean ?
a) Name of the medicine
2nd Year / Pharmacy. b) Once Daily
Subject : Community Pharmacy & Management. c) How to take the medicine
Time : 3 Hrs. M.M. : 80 d) Quantity to be dispensed
Q.7 Before taking a prescription medicine, you should know
SECTION-A which of the following ?
Note: One word / Multiple choice question. All the a) How much to take
questions are compulsory (20x1=20) b) When to take it
Q.1 The word ‘Pharmacy’ is derived from the Greek word: c) Which side effects to expect
a) Pharmaces b) Pharma d) All of the above
c) Pharmacisto d) Pharmakon Q.8 Inscription is also called :
Q.2 NABP stands for: a) Eyes of the Prescription
a) National Association of Boards of Pharmacist. b) Head of the Prescription
b) National Association of Boards of Pharmacy. c) Body of the Prescription
c) National Associate of Boards of Pharmacy. d) Hand of the Prescription
d) National Association of Boards of Pharma.
Q.3 Which of the following drug does not require therapeutic Q.9 __________ is the first enemy of communication.
a) Clarity b) Noise
drug monitoring ?
a) Digitoxin b) Paracetamol c) Politeness d) Completeness
c) Diazepam d) Isoniazid Q.10 When speaking on a phone, what type of communication
Q.4 The heart of the patient counselling session is called : is being used ?
a) Preparing for the session a) Verbal
b) Opening the session b) Non-verbal
c) Counselling content c) Verbal & tone of voice
d) Closing the session d) Verbal & body language
Q.5 The following are the principles of inventory control Q.11 Chronic anaemia and multiple sclerosis are :
except: a) Allergic diseases
a) Accurate Forecasting b) Autoimmune diseases
b) Effective Replenishment
c) Regular Monitoring c) Hormonal diseases
d) Overstocking d) Hereditary diseases
(1) ER20-22T (2) ER20-22T
Q.12 Patient information leaflets (PIL’s) are provided by ? Q.23 Describe various parts of a prescription.
a) Supplier b) Manufacturer Q.24 Define patient counselling and mention benefits of patient
c) Retailer d) Pharmacist counselling.
Q.13 What are the benefits of medication adherence ? Q.25 Describe any three factors responsible for medication non-
a) Reduction in admissions and read missions adherence.
Q.26 What is the importance of heath screening services ?
b) Cost savings
Q.27 What do you understand about promotion of responsible self-
c) Patient satisfaction medication?
d) All of the above Q.28 Elaborate the need and role of a pharmacist in OTC
Q.14 The comparison of bioavailability between two dosage medication dispensing ?
forms is referred as: Q.29 What is the difference between e-health and digital health ?
a) Bioavailability b) Biopharmaceutics Q.30 What is elderly medical adherence ?
c) Bio-reference d) Bioequivalence Q.31 What precautions should be taken while dispensing a
Q.15 ________ is a commonly reported ADR of diuretic class prescription ?
of drugs SECTION-C
a) Hypokalemia b) Alopecia Note: Long answer type question. Attempt any six
c) Skin disorder d) Allergies questions out of seven questions. (6x5=30)
Q.16 In an ideal drug store, the inventory is : Q.32 Define dispensing errors and strategies to minimize
a) In excess them.
b) Inadequate Q.33 Define communication skills. What are the different
c) Measured elements of the communication skills.
d) At level between excessive and inadequate Q.34 Describe role and objective of pharmacists in health
Q.17 The symbol Rx means ________. screening services.
Q.18 DIS stands for _________. Q.35 Write short note on any two :
Q.19 Who is the architect of Indian Pharmaceutical Industry? a) Customer Relation Management
Q.20 Name the premier pharmaceutical association of b) Financial planning and Management.
pharmacists in India. c) Inventory Management.
SECTION-B d) Audit in pharmacies
Note: Short answer type questions .Attempt any ten Q.36 What should be considered while designing community
questions. (10x3=30) pharmacy ?
Q.21 Define Community pharmacy. What is difference between Q.37 What are the strategies to overcomes barriers associated
community pharmacy and Hospital pharmacy. with patient counselling ?
Q.22 What are the roles and responsibilities of a community Q.38 Explain patient counselling points for Hypertension.
pharmacist ?
(3) (1720) (4) ER20-22T
ER20-22T
 No. of Printed Pages : 8 ER20-22T ç-7 fçfLØI'ku okyh nok ysus ls igys vkidks fuEufyf•r esa ls D;k tkuuk
Roll No. .................. pkfg,\
d) fdruh ysuh gS [k) dc ysuh gS
2nd Year / Pharmacy.
Subject : Community Pharmacy & Management. x) dkSu ls lkbM biQsDV~l dh mEehn djuh pkfg,
?k) mijksDr lHkh
Time : 3 Hrs. M.M. : 80 ç-8 balfØI'ku dks Hkh dgk tkrk gS%
Hkkx & d d) fçfLØI'ku dh vka• [k) fçfLØI'ku dk flj
uksV%& cgq fodYih; ç'uA lHkh ç'u vfuok;Z gSaA (20x1=20) x) fçfLØI'ku dk 'kjhj ?k) fçfLØI'ku dk gkFk
ç-1 ^iQkeZslh* 'kCn xzhd 'kCn ls fy;k x;k gS% ç-9 __________ lapkj dk igyk nq'eu gSA
d) iQkeZslhl [k) iQkekZ d) Li"Vrk [k) 'kksj
x) iQkekZflLVks ?k) iQkekZdkWu x) f'k"Vrk ?k) iw.kZrk
ç-2 NABP dk iwjk :i D;k gS\ ç-10 iQksu ij ckr djrs le;] fdl çdkj dk lapkj mi;ksx fd;k tk jgk gS\
d) jk"Vªh; iQkekZflLV cksM~lZ dk la?k d) ekSf•d
[k) jk"Vªh; iQkeZslh cksM~lZ dk la?k [k) xSj&ekSf•d
x) jk"Vªh; iQkeZslh cksM~lZ dk lg;ksxh
x) ekSf•d vkSj vkokt dk Loj
?k) jk"Vªh; iQkekZ cksM~lZ dk la?k
?k) ekSf•d vkSj 'kkjhfjd Hkk"kk
ç-3 fuEufyf•r esa ls dkSu lh nok ds fy, fpfdRlh; nok fuxjkuh dh
vko';drk ugha gksrh\ ç-11 Øksfud ,uhfe;k vkSj eYVhiy LDysjksfll gSa%
d) fMftVkWfDlu [k) iSjkflVkeksy d) ,ythZtU; jksx [k) vkRedqiks"kd jksx
x) Mk;tsike ?k) vk;lksfu;kftM x) gkekZsuy jksx ?k) oa'kkuqxr jksx
ç-4 jksxh ijke'kZ l=k dk eq[; fgLlk dgykrk gS% ç-12 jksxh tkudkjh i=kd (PIL's) fdlds }kjk çnku fd, tkrs gSa\
d) l=k ds fy, rS;kjh [k) l=k dh 'kq#vkr d) vkiwfrZdrkZ [k) fuekZrk
x) ijke'kZ lkexzh ?k) l=k dk lekiu x) fjVsyj ?k) iQkekZflLV
ç-5 fuEufyf•r esa ls dkSu lk bUosaVªh fu;a=k.k dk fl¼kar ugha gS\**
ç-13 nokvksa ds ikyu (Medication Adherence) ds D;k ykHk gSa\
d) lVhd iwokZuqeku [k) çHkkoh iqu%iwfrZ
d) vLirky esa HkrhZ vkSj iqu% HkrhZ esa deh
x) fu;fer fuxjkuh ?k) vf/d LVkWd djuk
[k) ykxr esa cpr
ç-6 'O.D.' tks fçfLØI'ku ij fy•k gksrk gS] bldk D;k eryc gS\
x) jksxh larqf"V
d) nok dk uke [k) fnu esa ,d ckj
?k) mijksDr lHkh
x) nok ysus dk rjhdk ?k) forfjr dh tkus okyh ek=kk
(5) ER20-22T (6) ER20-22T
ç-14 nks nokb;ksa ds :iksa ds chp tSomiyC/rk dh rqyuk dks D;k dgk tkrk ç-27 ftEesnkj Lo&fpfdRlk (Self-medication) dks c<+kok nsus ds ckjs esa
gS\ vki D;k le>rs gSa\
d) tSomiyC/rk [k) ck;ksiQkekZL;wfVDl ç-28 OTC (vksoj&n&dkmaVj) nokb;k¡ forfjr djus esa iQkekZflLV dh
x) ck;ks&jsiQjsal ?k) ck;ksbfDookysal vko';drk vkSj Hkwfedk dks foLrkj ls le>k,aA
ç-15 _________ Mk;;wjsfVd oxZ dh nokvksa dk lkekU; :i ls fjiksVZ ç-29 bZ&LokLF; (e-health) vkSj fMftVy LokLF; (digital health) ds chp
fd;k x;k ,d nq"çHkko (ADR) gSA D;k varj gS\
d) gkbiksdsyfe;k [k) ,yksisfl;k (cky >M+uk) ç-30 o`¼koLFkk esa nok ikyu (elderly medical adherence) D;k gS\
x) Ropk fodkj ?k) ,ythZ ç-31 fçfLØI'ku dks forfjr djrs le; dkSu lh lko/kfu;k¡ cjruh pkfg,\
ç-16 ,d vkn'kZ Mªx LVksj esa bUosaVªh dSlh gksrh gS\ Hkkx & x
d) vR;f/d [k) vi;kZIr uksV%& nh?kZ mÙkjh; ç'uA 7 esa ls fdUgha 6 ç'uksa dks gy dhft,A
x) ekih xbZ (6x5=30)
?k) vR;f/d vkSj vi;kZIr ds chp Lrj ij ç-32 fMLisaflax =kqfV;k¡ dh ifjHkk"kk nsa vkSj mUgsa de djus ds fy, j.kuhfr;k¡
crk,aA
ç-17 Rx çrhd dk D;k eryc gS\ ç-33 lapkj dkS'ky (Communication Skills) dh ifjHkk"kk nsaA lapkj dkS'ky
ç-18 DIS dk iwjk :i D;k gS\ ds fofHkUu rRo D;k gSa\
ç-19 Hkkjrh; iQkekZL;wfVdy m|ksx ds vkfdZVsDV dkSu gSa\ ç-34 LokLF; LØhfuax lsokvksa esa iQkekZflLV dh Hkwfedk vkSj mís'; dk o.kZu
ç-20 Hkkjr esa iQkekZflLVksa dk çeq• iQkekZL;wfVdy la?k dk uke D;k gS\ djsaA
Hkkx & [k ç-35 fuEufyf•r esa ls fdlh nks ij laf{kIr uksV fy•sa%
uksV%& y?kq mÙkjh; ç'uA 11 esa ls fdUgha 10 ç'uksa dks gy dhft,A d) xzkgd laca/ çca/u (Customer Relation Management)
(10x3=30) [k) foÙkh; ;kstuk vkSj çca/u (Financial Planning and
ç-21 lkeqnkf;d iQkeZslh dh ifjHkk"kk nsaA lkeqnkf;d iQkeZslh vkSj vLirky Management)
iQkeZslh ds chp varj D;k gS\ x) bUosaVªh çca/u (Inventory Management)
?k) iQkeZsfl;ksa esa vkWfMV (Audit in Pharmacies)
ç-22 lkeqnkf;d iQkekZflLV dh Hkwfedk,¡ vkSj ftEesnkfj;k¡ D;k gSa\
ç-36 lkeqnkf;d iQkeZslh (Community Pharmacy) fMtkbu djrs le; D;k
ç-23 fçfLØI'ku ds fofHkUu Hkkxksa dk o.kZu djsaA ckrksa dk è;ku j•uk pkfg,\
ç-24 jksxh ijke'kZ dh ifjHkk"kk nsa vkSj jksxh ijke'kZ ds ykHk crk,aA ç-37 jksxh ijke'kZ (Patient Counselling) ls lacaf/r ck/kvksa dks nwj djus ds
ç-25 nokb;ksa ds ikyu (Medication Adherence) esa foiQyrk ds ftEesnkj fy, dkSu lh j.kuhfr;k¡ viukbZ tk ldrh gSa\
rhu dkj.kksa dk o.kZu djsaA ç-38 gkbijVsa'ku (Hypertension) ds fy, jksxh ijke'kZ fcanqvksa (Patient
ç-26 LokLF; LØhfuax lsokvksa dk D;k egRo gS\ Counselling Points) dks le>k,aA

(7) ER20-22T (1720) (8) ER20-22T

 No. of Printed Pages : 8 ER20-23T Q.9 Write full form of PUFA
Roll No. .................. Q.10 How many amino acids make a protein ?
a) 10 b) 30
2nd Year / Pharmacy.
Subject : Biochemistry and Clinical Pathology c) 40 d) 20
Q.11 Which factor is not responsible for denaturation of
Time : 3 Hrs. M.M. : 80 proteins ?
SECTION-A a) PH b) Heat
Note: One word / Multiple choice questions. All questions c) Charge d) Organic solvent
are compulsory (20x1=20) Q.12 Complex IV / Complex 4 is also known as ______.
Q.1 The condition in which colour of the sclera of the Q.13 Any substance that contains free ions with the
eyes and skin become yellow ? property of electrical conductance is known as ?
a) Jaundice b) Yellow fever a) Electrolyte b) Vitamins
c) Plaque d) Congo fever c) Proteins d) Mineral
Q.2 Bile salts are absent in ? Q.14 In_____ tissue culture techniques were developed.
a) Pancreas b) Intestine a) 1905 b) 1908
c) Urine d) Stomach c) 1907 d) 1900
Q.3 Write full form of VLDL. Q.15 The normal range of prothrombin time is ?
Q.4 _____ is known as cane sugar. a) 1-6 seconds b) 12-16 seconds
Q.5 The normal life span of RBC is ? c) 12-16 minute d) 12-16 hours
a) 10 days b) 120 days Q.16 Which blood cells secrete antibody?
c) 200 days d) 100 days a) Eosinophils b) Monocytes
Q.6 Enzymes responsible for citric acid cycle are found c) Lymphocytes d) Neutrophils
in ? Q.17 The monomer unit of lipid is ?
a) Nucleus b) Ribosomes a) Glucose b) Fatty acids
c) Mitochondria d) ER c) Ribonucleotides d) Amino acid
Q.7 Direction of DNA synthesis is __________. Q.18 Which one of the following is a non-reducing sugar ?
Q.8 Proteins undergo breakdown into smaller units
a) Maltose b) Mannose
called ____________.
c) Sucrose d) Lactose
(1) ER20-23T (2) ER20-23T
Q.19 What color is Ninhydrin test ? SECTION-C
a) Blue to violet b) Blue to brown Note: Long answer type questions. Attempt any six
c) Blue to green d) Blue to black questions out of seven questions. (6x5=30)
Q.20 Aldolase belongs to which class of enzymes______. Q.32 Describe urea cycle
SECTION-B Q.33 Elaborate the normal and abnormal constituents of
Note: Short answer type questions. Attempt any ten urine including their significance and laboratory
questions out of Eleven questions. (10x3=30) tests to detect them.
Q.21 Define Enzymes. Mentions its IUB classification. Q.34 Explain the factors affecting enzyme activity
Q.22 Mention types of RNA and their functions Q.35 Give the stricture of sucrose and maltose along
Q.23 Give the structure of: with the test to identify them.
a) Glucose b) Fructose Q.36 Mention the dietary sources, functions and deficiency
c) Galactose manifestation of vitamin A.
Q.24 Define nucleic acid. Give difference between Q.37 Describe the scope of biochemistry in pharmacy.
nucleosides and nucleotides. Q.38 Write a note on disease related to abnormal
Q.25 Define proteins. Give biological signification of metabolism of amino acids.
proteins.
Q.26 What are essential amino acids ? Give example and
mention its significance.
Q.27 What is alkaptonuria ? Mention its causes,
symptoms and treatments.
Q.28 List the dietary sources of electrolytes.
Q.29 Write about the role of platelets in health and disease.
Q.30 Define Glycogenolysis and Glycogenesis. Give its
significance.
Q.31 What is oral rehydration therapy.

(3) (1920) (4) ER20-23T

ER20-23T
 No. of Printed Pages : 8 ER20-23T ç-10 fdrus vehuks ,flM (Amino acids) feydj ,d çksVhu (Protein)
Roll No. .................. cukrs gSa\
d) 10 [k) 30
2nd Year / Pharmacy.
Subject : Biochemistry and Clinical Pathology x) 40 ?k) 20
ç-11 dkSu lk dkjd çksVhu ds fMuSpqjs'ku (denaturation) ds fy, ftEesnkj
Time : 3 Hrs. M.M. : 80 ugha gS\
Hkkx & d d) pH [k) xehZ
uksV%& cgq fodYih; ç'uA lHkh ç'u vfuok;Z gSaA (20x1=20) x) pktZ ?k) dkcZfud ?kksy (Organic solvent)
ç-1 og fLFkfr ftlesa vka•ksa ds Lyhjk (sclera) vkSj Ropk dk jax ihyk gks ç-12 dkWEIysDl IV @ dkWEIysDl 4 dks fdl uke ls Hkh tkuk tkrk gS\
tkrk gS] D;k dgykrh gS\ ç-13 og inkFkZ tks Lora=k vk;uksa (free ions) dks bysfDVªdy daMD'ku
d) ihfy;k (Jaundice) [k) ;syks iQhoj (Yellow fever) (electrical conductance) dh fo'ks"krk ds lkFk daVsu djrk gS] mls D;k
x) Iysx (Plaque) ?k) dkaxks iQhoj (Congo fever) dgk tkrk gS\
ç-2 ckby lkWYV~l fdlesa vuqifLFkr gksrs gSa\ d) bysDVªksykbV (Electrolyte) [k) foVkfeu (Vitamins)
d) vXU;k'k; (Pancreas) [k) vkar (Intestine) x) çksVhu (Proteins) ?k) •fut (Mineral)
x) ew=k (Urine) ?k) isV (Stomach) ç-14 _____ esa Ård laLÑfr (tissue culture) rduhdsa fodflr dh xbZaA
ç-3 VLDL dk iwjk :i fy•saA d) 1905 [k) 1908
ç-4 _____ dks xUus dh phuh (Cane sugar) ds :i esa tkuk tkrk gSA x) 1907 ?k) 1900
ç-5 RBC dk lkekU; thoudky (life span) D;k gS\ ç-15 çksFkzksfEcu le; (prothrombin time) dk lkekU; ekud D;k gS\
d) 10 fnu [k) 120 fnu d) 1&6 lsdaM [k) 12&16 lsdaM
c) 200 fnu ?k) 100 fnu x) 12&16 feuV ?k) 12&16 ?kaVs
ç-6 lkbfVªd ,flM pØ (Citric acid cycle) ds fy, ftEesnkj ,atkbe dgk¡ ç-16 dkSu ls jDr dksf'kdk,¡ (blood cells) ,aVhckWMh (antibody) dk lzko
ik, tkrs gSa\ (secrete) djrh gSa\
d) ukfHkd (Nucleus) [k) jkbckslkse (Ribosomes) d) bvksfluksfiQYl (Eosinophils) [k) eksukslkbV~l (Monocytes)
x) ekbVksdkWfUMª;k (Mitochondria) x) fyEiQkslkbV~l (Lymphocytes) ?k) U;wVªksfiQYl (Neutrophils)
?k) ER (Endoplasmic Reticulum) ç-17 fyfiM (lipid) dh eksuksej bdkbZ (monomer unit) D;k gS\
ç-7 DNA la'ys"k.k (DNA synthesis) dh fn'kk __________ gSA
d) Xywdkst (Glucose)
[k) iQSVh ,flM~l (Fatty acids)
ç-8 çksVhu NksVs bdkb;ksa esa VwVdj __________ esa cny tkrs gSaA x) jkbcksU;wfDy;ksVkbM~l (Ribonucleotides)
ç-9 PUFA dk iwjk :i fy•saA ?k) vehuks ,flM (Amino acid)
(5) ER20-23T (6) ER20-23T
ç-18 fuEufyf•r esa ls dkSu lk ,d xSj&Reducing phuh (non-reducing iz-27 vydkIVksuqfj;k (Alkaptonuria) D;k gS\ blds dkj.k y{k.k
sugar) gS\ (symptoms) vkSj mipkj (treatments) dk mYys• djsaA
d) ekYVkst (Maltose) [k) eSukst (Mannose) iz-28 bysDVªksykbV~l (Electrolytes) ds vkgkj lzksrksa (dietary sources) dh
x) lqØkst (Sucrose) ?k) ySDVkst (Lactose) lwph nsaA
ç-19 fuugkbfMªu ijh{k.k (Ninhydrin test) dk jax D;k gksrk gS\ iz-29 IysVysV~l (Platelets) dh LokLF; vkSj jksx esa Hkwfedk (role) ds ckjs esa
d) uhyk ls cSaxuh (Blue to violet) fy•saA
[k) uhyk ls Hkwjk (Blue to brown) iz-30 Xykbdkstuksfyfll (Glycogenolysis) vkSj Xykbdkstsufll
x) uhyk ls gjk (Blue to green) (Glycogenesis) dh ifjHkk"kk nsaA blds egRo (significance) dk o.kZu
?k) uhyk ls dkyk (Blue to black) djsaA
ç-20 ,YMksykt (Aldolase) fdl oxZ ds ,atkbe (class of enzymes) ls iz-31 ekSf•d iqu% ty;kstu mipkj (Oral Rehydration Therapy) D;k gS\
lacaf/r gS\ Hkkx & x
Hkkx & [k uksV%& nh?kZ mÙkjh; ç'uA 7 esa ls fdUgha 6 ç'uksa dks gy dhft,A
uksV%& y?kq mÙkjh; ç'uA 11 esa ls fdUgha 10 ç'uksa dks gy dhft,A (6x5=30)
(10x3=30) iz-32 ;wfj;k pØ (Urea cycle) dk fooj.k nsaA
iz-21 ,atkbEl (Enzymes) dh ifjHkk"kk nsaA blds IUB oxhZdj.k (IUB iz-33 ew=k (Urine) ds lkekU; vkSj vlkekU; ?kVdksa (constituents) dk
classification) dk mYys• djsaA foLrkj ls o.kZu djsa] muds egRo (significance) lfgr] vkSj mUgsa
iz-22 RNA ds çdkj (types of RNA) vkSj muds dk;Z (functions) dk igpkuus ds fy, ç;ksx'kkyk ijh{k.k (laboratory tests) dk mYys•
mYys• djsaA djsaA
iz-23 fuEufyf•r dh lajpuk (structure) nsa% iz-34 ,atkbe xfrfof/ (enzyme activity) dks çHkkfor djus okys dkjdksa
d) Xywdkst (Glucose) [k) ÚqDVkst (Fructose) (factors) dk o.kZu djsaA
x) xSySDVkst (Galactose) iz-35 lqØkst (Sucrose) vkSj ekYVkst (Maltose) dh lajpuk (structure) nsa
iz-24 U;wfDyd ,flM (Nucleic acid) dh ifjHkk"kk nsaA U;wDykslkbM~l vkSj bUgsa igpkuus ds ijh{k.k (test) dk mYys• djsaA
(nucleosides) vkSj U;wfDy;ksVkbM~l (nucleotides) ds chp dk varj iz-36 foVkfeu A (Vitamin A) ds vkgkj lzksr (dietary sources)] dk;Z
(difference) nsaA (functions) vkSj deh (deficiency) ds y{k.k (manifestations) dk
iz-25 çksVhu (Proteins) dh ifjHkk"kk nsaA çksVhu dk tSfod egRo (biological mYys• djsaA
significance) crk,aA iz-37 iQkeZslh esa ck;ksdSfeLVªh (Biochemistry) dk nk;jk (scope) D;k gS]
iz-26 vko';d vehuks ,flM~l (Essential amino acids) D;k gksrs gSa\ bldk fooj.k nsaA
mnkgj.k (example) nsa vkSj blds egRo (significance) dk mYys• iz-38 vehuks ,flM~l (Amino acids) ds vlkekU; esVkcksfyTe (abnormal
djsaA metabolism) ls lacaf/r jksxksa (diseases) ij ,d uksV fy•saA

(7) ER20-23T (1920) (8) ER20-23T

 No. of Printed Pages : 8 ER20-24T Q.6 What is non-pharmacological management for diabetes?
Roll No. .................. a) Regular exercise b) Weight loss
2nd Year / Pharmacy. c) Low-sugar diet d) All of the above
Q.7 What is the definition of epilepsy ?
Subject : Pharmacotherapeutics a) Neurodegenerative disorder
Time : 3 Hrs. M.M. : 80 b) Chronic pain syndrome
SECTION-A c) Recurrent seizures
Note: Multiple choice question. All the questions are d) Progressive muscle weakness
compulsory (20x1=20) Q.8 What is the etiopathogenesis of Alzheimer’s disease?
a) Inadequate blood supply to the brain
Q.1 What is the definition of hypertansion ? b) Excessive accumulation of beta-amlyoid protein in
a) Abnormally low blood pressure the brain
b) Abnormally high blood pressure c) Abnormal brain cell communication
c) Abnormal heart rhythm d) All of the above
d) Abnormal heart valve function. Q.9 What is the clinical manifestation of peptic ulcer disease?
Q.2 What is the etiopathogenesis of angina and myocardial a) Abdominal pain and discomfort
infarction ? b) Chest pain
a) Excessive cholesterol intake c) Shortness of breath d) Edema
b) Inadequate body supply to the heart muscle Q.10 What is the non-pharmacological management of
c) Excessive physical activity alcoholic liver disease ?
d) Genetic predisposition a) Abstinence from alcohol and healthy life style
Q.3 What is the etiopathogenesis of COPD ? changes
a) Exposure to environmental pollutants b) Anti-alcoholic medications
b) Viral infection c) Coronary angiography
c) Genetic predisposition d) Stenting
d) All of the above Q.11 What is the clinical manifestation of stroke ?
Q.4 What are the clinical manifestations of asthma ? a) Sudden weakness or numbness on one side of the
a) Chest tightness and cough body
b) Wheezing and shortness of breath b) Chest pain
c) Fever and chills c) Shortness of breath d) Edema
d) No specific symptoms Q.12 What is the non-pharmacological management of
Q.5 What is non-pharmacological management for migraine ?
congestive heart failure ? a) Avoiding triggers and regular exercise
b) Antimigraine medications
a) Regular exercise b) Smoking cessation
c) Coronary angiography
c) Low-salt diet d) All of the above
d) Stenting
(1) ER20-24T (2) ER20-24T
Q.13 Which of the following is the most common cause of iron Q.22 Write about the scope and objective of the
deficiency anaemia ? pharmacotherapeutics.
a) Inadequate dietary intake b) Blood loss Q.23 Explain purpose and content of standard treatment
c) Increased iron utilization d) Decreased absorption guidelines.
Q.14 Megaloblastic anaemia is most commonly caused by a Q.24 Explain the pathogenesis and pharmacological treatment
deficiency of which vitamin ? of peptic Ulcer
a) Vitamin C b) Vitamin D Q.25 Mention the classification and clinical manifestation of
c) Vitamin B12 d) Viatmin A Hyperlipidaemia.
Q.15 Which of the following is a clinical manifestation of iron Q.26 Define Dysmenorrhea. Give an account of its types,
deficiency anaemia ? diagnosis & Management.
a) Jaundice b) Peripheral neuropathy Q.27 Classify diabetes and write their etiopathogenesis.
c) Glossitis d) Hyperpigmentation Q.28 Define the clinical manifestation of angina OR alcoholic
Q.16 The schilling test is used to diagnose which type of liver disease.
anaemia ? Q.29 Describe etiopathagenesis and non-pharmacological
a) Iron deficiency anaemia b) Megaloblastic anaemia management of the HIV
c) Haemolytic anaemia d) Aplastic anaemia Q.30 Discuss in detail about pathophysiology and non-
Q.17 Which of the following is a sexually transmitted pharmacological treatment of stroke.
infection caused by a bacterium ? Q.31 Define Pneumonia. Give an account of its types,
a) Malaria b) HIV pathophysiology, diagnosis & treatment.
c) Gonorrhea d) Hepatitis C SECTION-C
Q.18 Which of the following is a viruses causes COVID-19 ? Note: Long answer type question. Attempt any six questions
out of seven questions. (6x5=30)
a) Influenza virus b) SARS-CoV-2 Q.32 What are the pharmacological treatments for the
c) Ebola virus d) Zika virus tuberculosis
Q.19 Which of the following is a common symptom of Q.33 What are the symptoms & pharmacological treatment for
osteoarthritis ? depression
a) Joint swelling b) Joint stiffness Q.34 Write down the factor contributing in antimicrobial
c) Joint redness d) Joint deformity drug resistance.
Q.20 Which skin condition is caused by a mite infestation? Q.35 Write short notes on any two:
a) Psoriasis b) Scabies a) Eczema b) Migraine c) Hypothyroidism
c) Eczema d) Rosacea Q.36 Explain steps to be taken to prevent spreading of
SECTION-B COVID-19
Note: Short answer type question. Attempt any ten questions Q.37 Explain in detail about pharmacological management
(10x3=30) of hypertension.
Q.21 What is COPD ? Explain clinical manifestation of COPD Q.38 Explain in detail about pharmacological treatment of
in detail. Crohn’s disease.
(3) (1900) (4) ER20-24T
ER20-24T
 No. of Printed Pages : 8 ER20-24T
Roll No. .................. ç-6 Mk;fcVht ds fy, xSj&iQkekZdksykWftdy çca/u D;k gS\
d) fu;fer O;k;ke [k) otu ?kVkuk
2nd Year / Pharmacy. x) de phuh okyh vkgkj ?k) mijksDr lHkh
Subject : Pharmacotherapeutics ç-7 fexhZ dh ifjHkk"kk D;k gS\
d) U;wjksMhtsusjsfVo fodkj [k) iqjkuh nnZ flaMªkse
Time : 3 Hrs. M.M. : 80 x) vkorhZ nkSjs
Hkkx & d ?k) çxfr djus okyh ekalisf'k;ksa dh detksjh
uksV%& cgq fodYih; ç'uA lHkh ç'u vfuok;Z gSaA (20x1=20) ç-8 vYtkbej jksx dh ,VhvksiSFkkstsusfll D;k gS\
ç-1 gkbijVsa'ku dh ifjHkk"kk D;k gS\ d) efLr"d dks vi;kZIr jDr vkiwfrZ
d) vlkekU; :i ls de jDrpki [k) vlkekU; :i ls mPp jDrpki [k) efLr"d esa chVk&,feykW;M çksVhu dk vR;f/d lap;
x) vlkekU; ân; fjne ?k) vlkekU; ân; okYo dk;Z x) efLr"d dksf'kdkvksa ds vlkekU; lapkj
?k) mijksDr lHkh
ç-2 ,atkbuk vkSj ek;ksdkfMZ;y bUiQkD'kZu dh ,VhvksiSFkkstsusfll D;k gS\
ç-9 isfIVd vYlj jksx dk fDyfudy y{k.k D;k gS\
d) vR;f/d dksysLVªkWy dk lsou d) isV esa nnZ vkSj vlqfo/k [k) lhus esa nnZ
[k) ân; is'kh dks vi;kZIr jDr vkiwfrZ x) lkal dh deh ?k) lwtu
x) vR;f/d 'kkjhfjd xfrfof/ ç-10 'kjkch fyoj jksx dk xSj&iQkekZdksykWftdy çca/u D;k gS\
?k) vkuqoaf'kd ço`fÙk d) 'kjkc ls cpko vkSj LoLFk thou'kSyh esa cnyko
ç-3 COPD dh ,VhvksiSFkkstsusfll D;k gS\ [k) ,aVh&vYdksgy nokb;k¡
d) i;kZoj.kh; çnw"kdksa ds laidZ esa vkuk x) dksjksujh ,aft;ksxzkiQh ?k) LVsafVax
[k) ok;jy laØe.k ç-11 LVªksd ds fDyfudy y{k.k D;k gSa\
x) vkuqoaf'kd ço`fÙk ?k) mijksDr lHkh d) 'kjhj ds ,d rjiQ vpkud detksjh ;k lqUurk
[k) lhus esa nnZ
ç-4 vLFkek ds fDyfudy y{k.k D;k gSa\
x) lkal dh deh ?k) lwtu
d) Nkrh esa ncko vkSj •kalh ç-12 ekbxzsu ds xSj&iQkekZdksykWftdy çca/u D;k gS\
[k) ?kj?kjkgV vkSj lkal dh deh d) fVªxlZ ls cpuk vkSj fu;fer O;k;ke
x) cq•kj vkSj BaM [k) ,aVhekbxzsu nokb;k¡
?k) dksbZ fo'ks"k y{k.k ugha x) dksjksujh ,aft;ksxzkiQh ?k) LVsafVax
ç-5 dkWUtsfLVo gkVZ iQsY;ksj ds fy, xSj&iQkekZdksykWftdy çca/u D;k gS\ ç-13 fuEufyf•r esa ls vk;ju dh deh ls gksus okyh ,uhfe;k dk lcls lkekU;
d) fu;fer O;k;ke [k) /weziku lekiu dkj.k D;k gS\**
x) de ued okyh vkgkj ?k) mijksDr lHkh d) vi;kZIr vkgkj lsou [k) jDr dh gkfu
x) vk;ju dk vf/d mi;ksx ?k) vo'kks"k.k esa deh
(5) ER20-24T (6) ER20-24T
ç-14 esxkyksCykfLVd ,uhfe;k lcls lkekU; :i ls fdl foVkfeu dh deh ds iz-22 iQkekZdksFksjsI;wfVDl dk nk;jk vkSj mís'; fy•saA
dkj.k gksrk gS\ iz-23 ekud mipkj fn'kkfunZs'kksa dk mís'; vkSj lkexzh le>k,aA
d) foVkfeu C [k) foVkfeu D iz-24 isfIVd vYlj dh iSFkkstsusfll vkSj iQkekZdksykWftdy mipkj le>k,aA
x) foVkfeu B12 ?k) foVkfeu A iz-25 gkbijfyfiMsfe;k dk oxhZdj.k vkSj fDyfudy y{k.k mYys• djsaA
ç-15 fuEufyf•r esa ls dkSu lk vk;ju dh deh ls gksus okyh ,uhfe;k dk ,d iz-26 fMlesuksfj;k dh ifjHkk"kk nsaA blds çdkj] funku vkSj çca/u ij fooj.k nsaA
fDyfudy y{k.k gS\ iz-27 Mk;fcVht dk oxhZdj.k djsa vkSj mudh ,VhvksiSFkkstsusfll fy•saA
a d) ihfy;k [k) isfjiQsjy U;wjksiSFkh iz-28 ,atkbuk ;k 'kjkch fyoj jksx ds fDyfudy y{k.k ifjHkkf"kr djsaA
x) XykslkbfVl ?k) gkbijfiXesaVs'ku iz-29 HIV dh ,VhvksiSFkkstsusfll vkSj xSj&iQkekZdksykWftdy çca/u dk o.kZu djsaA
ç-16 f'kfyax ifj{k.k dk mi;ksx fdl çdkj dh ,uhfe;k dk funku djus ds fy, iz-30 LVªksd dh iSFkksfiQft;ksykWth vkSj xSj&iQkekZdksykWftdy mipkj ij foLrkj ls
fd;k tkrk gS\ ppkZ djsaA
d) vk;ju dh deh ls gksus okyh ,uhfe;k iz-31 U;weksfu;k dh ifjHkk"kk nsaA blds çdkj] iSFkksfiQft;ksykWth] funku vkSj mipkj
[k) esxkyksCykfLVd ,uhfe;k ij fooj.k nsaA
x) gheksfyfVd ,uhfe;k ?k) ,IykfLVd ,uhfe;k Hkkx & x
ç-17 fuEufyf•r esa ls dkSu lk ;kSu lapkfjr laØe.k ,d cSDVhfj;k ds dkj.k gksrk uksV%& nh?kZ mÙkjh; ç'uA 7 esa ls fdUgha 6 ç'uksa dks gy dhft,A
gS\ (6x5=30)
d) eysfj;k [k) HIV iz-32 risfnd (TB) ds fy, iQkekZdksykWftdy mipkj D;k gSa\
x) xksuksfj;k ?k) gsisVkbfVl C iz-33 fMçs'ku ds y{k.k vkSj iQkekZdksykWftdy mipkj D;k gSa\
ç-18 fuEufyf•r esa ls dkSu lk ok;jl dksfoM&19 dk dkj.k curk gS\ iz-34 ,aVhekbØksfc;y Mªx jsftLVsal esa ;ksxnku djus okys dkjd fy•saA
d) bUÝyw,atk ok;jl [k) SARS-CoV-2 iz-35 fuEufyf•r esa ls fdlh nks ij laf{kIr uksV fy•sa%
x) bcksyk ok;jl ?k) thdk ok;jl d) ,fDtek b) ekbxzsu
ç-19 fuEufyf•r esa ls dkSu lk vkWfLV;ksvkFkZjkbfVl dk lkekU; y{k.k gS\ c) gkbiksFkk;jk;fMt~e
d) tksM+ esa lwtu [k) tksM+ esa vdM+u iz-36 COVID&19 ds iQSyko dks jksdus ds fy, mBk, tkus okys dneksa dk foLrkj
x) tksM+ esa ykyh ?k) tksM+ esa foÑfr ls o.kZu djsaA
ç-20 fuEufyf•r esa ls dkSu lk Ropk jksx ekbV~l ds laØe.k ds dkj.k gksrk gS\ iz-37 gkbijVsa'ku ds iQkekZdksykWftdy çca/u ds ckjs esa foLrkj ls le>k,aA
d) lksjk;fll [k) •qtyh iz-38 Øksgu jksx ds iQkekZdksykWftdy mipkj ds ckjs esa foLrkj ls le>k,aA
x) ,fDtek ?k) jkstsfl;k
Hkkx & [k
uksV%& y?kq mÙkjh; ç'uA 11 esa ls fdUgha 10 ç'uksa dks gy dhft,A
(10x3=30)
iz-21 COPD D;k gS\ COPD ds fDyfudy y{k.kksa dks foLrkj ls le>k,aA

(7) ER20-24T (1900) (8) ER20-24T

 No. of Printed Pages : 8 ER20-25T Q.7 What is the importance of monitoring TPN therapy?
Roll No. .................. a) To ensure that the patient is receiving the proper
2nd Year / Pharmacy nutrients
Subject : Hospital And Clinical Pharmacy b) To prevent complications such as infection or
Time : 3 Hrs. M.M. : 80 metabolic imbalances
c) To monitor for adverse drug reactions.
SECTION-A d) All of the above
Note: One word / Multiple choice question. All questions Q.8 What is the role of a pharmacist in the emergency
are compulsory (20x1=20) ward ?
Q.1 What is the scope of Hospital Pharmacy. a) To prescribe medications for patients
a) Dispensing of medicines to patients b) To administer medications to patients
b) Preparation of sterile products c) To prepare and dispense medications for
c) Procurement and storage of drugs patients
d) All of the above d) To provide counselling to patients
Q.2 The total number of copies of purchase order Q.9 FEFO stands for______
prepared are ____________. a) First Expire First Out
a) 05 b) 06 b) First Exist First over
c) 07 d) 09 c) First Entry First Out
Q.3 The main function of a hospital is to provide d) None
__________to the sick or injured.
Q.10 Dimercaprol used to treat
a) Care b) Food
a) Arthritis b) Poisoning
c) Education d) Saline
c) Inflammation d) Anaemia
Q.4 Presence of protein in urine is known as _________.
Q.11 Which of the following test is glucose memory test ?
Q.5 Which of the following is a branch of medicine that
a) GCT b) HbA1C
focuses on the care of the elderly ?
c) GTT d) SGCT
a) Paediatrics b) Geriatrics
Q.12 Which of the following is a radio-opaque
c) Obstetrics d) Cardiology
compound?
Q.6 Cold storage temperature is ___________
a) Barium chloride b) Barium sulphate
a) 20C to 80C b) 100C to 140C
0 0 c) Barium oxide d) Barium phosphate
c) 15 C to 18 C d) None
(1) ER20-25T (2) ER20-25T
Q.13 What are some examples of drugs that may be Q.24 Describe pharmacovigilance and ICH regulation
included in a high-risk drug list ? Q.25 What is bulk compounding ?
a) Antibiotics b) Chemotherapy drugs Q.26 Write short note on dispensing of charged / non-
c) Narcotics d) All of the above charged floor stock drugs.
Q.14 What is the advantage of the individual prescription Q.27 Describe inventory control techniques.
order method of drug distribution ? Q.28 Write a short note on drug information service.
a) It is the most cost-effective method Q.29 Write down the risk asociated with intravenous (IV)
b) It minimizes the risk of medication errors therapy.
c) It promotes medication waste reduction Q.30 How to check your pulse ?
d) It allows for quick and easy access to Q.31 Define poisons along with their classification.
medications SECTION-C
Q.15 What is a NICU ? Note: Long answer type question. Attempt any six
a) Neonatal Intensive Care Unit questions out of seven questions. (6x5=30)
b) Neurological Intensive Care Unit Q.32 What are high risk drugs or high-alert drugs give 5
c) Nephrology Intensive Care Unit examples of high-risk drugs.
d) None of the above Q.33 Draw a layout, location and flowchart of materials
Q.16 How many beds are required for medium size and men in a pharmacy.
hospital ? Q.34 Draw and explain the location and layout of out-
Q.17 How many pharmacists are required for 100 beds patient dispensing OR what is TPN. What is the
hospital ? most common complication associated with
Q.18 Spirometry is used to test ________. parenteral nutrition ?
Q.19 A teratogenic drug causes toxicity of ________. Q.35 Write a detailed note on ADR.
Q.20 Write full form of CSSD. Q.36 Explain briefly about distribution and storage of
SECTION-B narcotic and psychotropic substances.
Note: Short answer type questions. Attempt any ten Q.37 Explain medication errors and their types.
questions out of Eleven questions. (10x3=30) Q.38 Explain how drug interaction occurs with both
Q.21 Explain the role of PTC. outside and inside the human body.
Q.22 Give the classification of hospitals.
Q.23 How do you handle expired drugs?

(3) (1840) (4) ER20-25T

ER20-25T
 No. of Printed Pages : 8 ER20-25T ç-6 BaMh HkaMkj.k rkieku D;k gksrk gS\
Roll No. .................. 0
d) 2 C to 8 C
0 0
[k) 10 C to 14 C
0

2nd Year / Pharmacy x) 150C to 180C ?k) dksbZ ugha

Subject : Hospital And Clinical Pharmacy ç-7 TPN (Total Parenteral Nutrition) Fksjsih dh fuxjkuh dk D;k egRo gS\
d) ;g lqfuf'pr djus ds fy, fd jksxh dks mfpr iks"kd rRo fey jgs gSa
Time : 3 Hrs. M.M. : 80 [k) laØe.k ;k p;kip; vlarqyu tSlh tfVyrkvksa dks jksdus ds fy,
Hkkx & d x) nok ds çfrdwy çfrfØ;kvksa dh fuxjkuh ds fy,
uksV%& cgq fodYih; ç'uA lHkh ç'u vfuok;Z gSaA (20x1=20) ?k) mijksDr lHkh
ç-1 vLirky iQkeZslh dk nk;jk D;k gS\ ç-8 vkikrdkyhu okMZ esa iQkekZflLV dh Hkwfedk D;k gS\
d) jksfx;ksa dks nokb;k¡ forfjr djuk d) jksfx;ksa ds fy, nok,¡ fu/kZfjr djuk
[k) futhZo mRiknksa (Sterile Products) dk fuekZ.k [k) jksfx;ksa dks nok,¡ nsuk
x) nokvksa dh •jhn vkSj HkaMkj.k x) jksfx;ksa ds fy, nokvksa dks rS;kj vkSj forfjr djuk
?k) mijksDr lHkh ?k) jksfx;ksa dks ijke'kZ çnku djuk
ç-2 dqy fdruh dkWfi;k¡ •jhn vkns'k dh rS;kj dh tkrh gSa\ ç-9 FEFO dk iwjk :i D;k gS\
d) 05 [k) 06 d) First Expire First Out [k) First Exist First Over
x) 07 ?k) 09 x) First Entry First Out ?k) dksbZ ugha
ç-3 vLirky dk eq[; dk;Z jksxh ;k ?kk;y O;fDr dks __________ ç-10 MkbedkZçksy dk mi;ksx fdl bykt ds fy, fd;k tkrk gS\
çnku djuk gSA d) xfB;k (Arthritis) [k) fo"kkDrrk (Poisoning)
d) ns•Hkky [k) Hkkstu x) lwtu (Inflammation) ?k) ,uhfe;k (Anaemia)
x) f'k{kk ?k) lykbu ç-11 fuEufyf•r esa ls dkSu lk Xywdkst eseksjh VsLV gS\
ç-4 ew=k esa çksVhu dh mifLFkfr dks ________ds uke ls tkuk tkrk gSA d) GCT [k) HbA1C
ç-5 fuEufyf•r esa ls dkSu lk fpfdRlk 'kk•k cqtqxks± dh ns•Hkky ij dsafær x) GTT ?k) SGCT
gS\ ç-12 fuEufyf•r esa ls dkSu lk jsfM;ks&vkWisDl ;kSfxd gS\**
a d) cky jksx (Paediatrics) d) cSfj;e DyksjkbM (Barium chloride)
[k) o`¼koLFkk fpfdRlk (Geriatrics) [k) cSfj;e lYiQsV (Barium sulphate)
x) çlwfr (Obstetrics) x) cSfj;e vkWDlkbM (Barium oxide)
?k) dkfMZ;ksykWth (Cardiology) ?k) cSfj;e iQkWLiQsV (Barium phosphate)
(5) ER20-25T (6) ER20-25T
ç-13 mPp&tksf•e okyh nokvksa dh lwph esa dkSu lh nok,¡ 'kkfey gks ldrh iz-23 lekIr (expired) nokvksa dks vki dSls laHkkyrs gSa\
gSa\ iz-24 iQkekZdksfoftysal vkSj ICH fofu;e dk o.kZu djsaA
d) ,aVhck;ksfVDl [k) dheksFksjsih nok,¡ iz-25 cYd daikmafMax D;k gS\
x) u'khyh nok,¡ ?k) mijksDr lHkh iz-26 pkTMZ @ ukWu&pkTMZ Ýyksj LVkWd nokvksa ds forj.k (Dispensing) ij
ç-14 nokb;ksa ds forj.k ds O;fDrxr vkns'k fof/ dk D;k ykHk gS\ laf{kIr uksV fy•saA
d) ;g lcls ykxr&çHkkoh fof/ gS iz-27 bUosaVªh fu;a=k.k (Inventory Control) dh rduhdksa dk o.kZu djsaA
[k) ;g nok xyfr;ksa ds tksf•e dks de djrk gS iz-28 nok tkudkjh lsok (Drug Information Service) ij ,d laf{kIr uksV
x) ;g nokvksa ds viO;; esa deh dks c<+kok nsrk gS fy•saA
?k) ;g nokvksa rd Rofjr vkSj vklku igq¡p çnku djrk gS iz-29 var%f'kjk (IV) fpfdRlk ls tqM+s tksf•eksa (Risk) dks fy•saA
ç-15 NICU D;k gS\ iz-30 viuh uCt (Pulse) dks dSls tkapsa\
d) uotkr xgu ns•Hkky bdkbZ (Neonatal Intensive Care Unit) iz-31 fo"k (Poisons) dh ifjHkk"kk nsa vkSj muds oxhZdj.k ds lkFk fy•saA
[k) U;wjksykWftdy xgu ns•Hkky bdkbZ (Neurological Intensive Hkkx & x
Care Unit) uksV%& y?kq mÙkjh; ç'uA 7 esa ls fdUgha 6 ç'uksa dks gy dhft,A
x) usÚksykWftdy xgu ns•Hkky bdkbZ (Nephrology Intensive (6x5=30)
Care Unit)
iz-32 mPp tksf•e okyh nok,¡ ;k mPp&vyVZ nok,¡ D;k gSa\ mPp&tksf•e
?k) mijksDr dksbZ ugha
okyh nokvksa ds 5 mnkgj.k nsaA
ç-16 ,d eè;e vkdkj ds vLirky ds fy, fdrus fcLrjksa dh vko';drk
iz-33 iQkeZslh esa lkexzh vkSj O;fDr;ksa ds fy, ysvkmV] LFkku vkSj ÝykspkVZ
gksrh gS\
cuk,aA
ç-17 100 fcLrjksa okys vLirky ds fy, fdrus iQkekZflLV dh vko';drk
iz-34 cká jksxh forj.k (Out&patient dispensing) dk LFkku vkSj ysvkmV
gksrh gS\
cuk,a vkSj le>k,a ;k Vh ih ,u D;k gS\ iSjsUVjy iks"k.k (Parenteral
ç-18 LikbjksesVªh dk mi;ksx fdldh tkap ds fy, fd;k tkrk gS\
Nutrition) ls tqM+h lcls lkekU; tfVyrk D;k gS\
ç-19 ,d VsjkVkstsfud nok fdldh fo"kkDrrk dk dkj.k curh gS\
iz-35 ADR (Adverse Drug Reactions) ij ,d foLr`r uksV fy•saA
ç-20 CSSD dk iwjk :i fy•saA
iz-36 u'khyh vkSj ekufld mRçsjd (psychotropic) inkFkks± ds forj.k vkSj
Hkkx & [k HkaMkj.k ds ckjs esa la{ksi esa le>k,aA
uksV%& oLrqfu"B ç'uA 11 esa ls 10 iz'uksa dks gy dhft,A (10x3=30) iz-37 nok dh xyfr;ksa (Medication Errors) vkSj muds çdkjksa dks le>k,aA
iz-21 PTC dh Hkwfedk dks le>k,aA iz-38 nok&çfrfØ;k (Drug Interaction) dSls gksrh gS] bls ckgjh vkSj
iz-22 vLirkyksa dh oxhZdj.k (Classification of Hospitals) nsaA vkarfjd :i ls ekuo 'kjhj esa dSls le>k tkrk gS\

(7) ER20-25T (1840) (8) ER20-25T

 No. of Printed Pages : 8 ER20-26T Q.8 Advertisement of drugs claiming cure of disease
Roll No. .................. mentioned in Schedule-j is
a) Granted b) Prohibited
2nd Year / Pharmacy.
Subject : Pharmacy Law & Ethics c) Exempted d) None of above
Q.9 Display signboard or notices by a registered medical
Time : 3 Hrs. M.M. : 80 pratitioner on his premises fall under
SECTION-A a) Regular advertisement
Note: One word / Multiple choice question. All questions b) Permitted advertisement
are compulsory (20x1=20) c) Exempted advertisement
Q.1 Drug Import Bill was passed in the year d) Prohibited advertisement
a) 1935 b) 1937 Q.10 According to the prevention of Cruelty to Animals
c) 1939 d) 1941 Act,1960, the word ‘animal’ means any living
Q.2 Write full form of IPR creature except.
Q.3 PCI was constituted in a) Birds b) Animals
a) 1919 b) 1948 c) Human Beings d) None of the above
c) 1949 d) 1942 Q.11 Biomedical waste Management, Rules came into
Q.4 The instruments of legislation are existence in the year _______
a) Act b) Section Q.12 The Poison Act came into existence in the year
c) Orders d) All of the above __________.
Q.5 PCI is reconstituted at every Q.13 What is the meaning of ED in the calculation of the
a) 1 year b) 2 years retail price of drugs ?
c) 4 years d) 5 years a) Excise duty b) Exempted duty
Q.6 The schedule for the life period of the drug is c) Extra duty d) Emergency Duty
a) Schedule Q b) Schedule P Q.14 The drugs prices Control Order is applicable to
c) Schedule R d) Schedule S
a) Ayurveda medicines
Q.7 Examples of Narcotic drugs
b) Unani Medicines
a) Opium b) Coca
c) Homoeopathic medicines
c) Hemp d) All of the above
d) Allopathic Medicines
(1) ER20-26T (2) ER20-26T
Q.15 The code of ethics of pharmacy is developed by Q.27 Write a short note on Penalties under Poisons Act,
a) PCI b) SPC 1919
c) MCI d) DCGI Q.28 Elaborate about the functions FSSAI
Q.16 What is full form of ICMR ? Q.29 Define Ceiling price and Market Price.
Q.17 Medical Termination of Pregnancy act was passed in Q.30 Explain about basic concept of clinical trials.
year Q.31 Write a short note on Consumer Protection Act.
a) 1965 b) 1971 SECTION-C
c) 1947 d) 1945 Note: Long answer type question. Attempt any six
Q.18 Where is the Head Quarter of CDSCO located ? questions. Out of seven question. (6x5=30)
a) Mumbai b) Kolkata Q.32 Elaborate the objectives of Drugs and Magic Remedies
c) Chennai d) Delhi (Objectionable Advertisements) Act, 1954
Q.19 How many Zonal offices of CDSCO are there ? Q.33 What are the duties and functions of Drug Technical
a) 6 b) 2 Advisory Board.
c) 4 d) 8 Q.34 Eloborate the functions and composition of the state
Q.20 Drug Regulatory body of India is __________. pharmacy councils and joint state pharmacy council.
SECTION-B Q.35 Write a short note on Termination of pregnancy by
Note: Attempt any ten questions out of Eleven questions. registered medical practitioners.
(10x3=30) Q.36 Explain briefly about the steps involved in Drug
Q.21 What are the functions of the Animal Welfare Board Development Process.
of India. Q.37 Describe the Offences & penalties as per the
Q.22 Describe the role of Schedules. C, G and H as per Narcotics & Psychotropic Substances Act.
Drugs and Cosmetic Act 1948 Q.38 Write short notes on any two :
Q.23 Explain principles of bioethics. a) Restricted License
Q.24 Explain the classes of Drugs & Cosmetics prohibited b) National list of essential medicines
from import. c) Biomedical Waste
Q.25 Write a short note on Licensing Authority
Q.26 Explain the role and responsibilities of Government
Analysts
(3) (1820) (4) ER20-26T
ER20-26T
 No. of Printed Pages : 8 ER20-26T ç-8 vuqlwph&ts (Schedule-j) esa mfYyf•r jksxksa ds bykt dk nkok
Roll No. .................. djus okyh nokvksa ds foKkiu dks ________ ekuk tkrk gSA
d) vuqeksfnr (Granted) [k) çfrcaf/r (Prohibited)
2nd Year / Pharmacy.
x) NwV (Exempted) ?k) mijksDr esa ls dksbZ ugha
Subject : Pharmacy Law & Ethics
ç-9 ,d iathÑr fpfdRlk is'ksoj }kjk muds ifjlj ij cksMZ ;k uksfVl
Time : 3 Hrs. M.M. : 80 fn•kuk ________ ds varxZr vkrk gSA
Hkkx & d d) fu;fer foKkiu (Regular Advertisement)
uksV%& cgq fodYih; ç'uA lHkh ç'u vfuok;Z gSaA (20x1=20) [k) vuqer foKkiu (Permitted Advertisement)
ç-1 nok vk;kr fo/s;d (Drug Import Bill) fdl o"kZ ikl gqvk Fkk\ x) NwV çkIr foKkiu (Exempted Advertisement)
d) 1935 [k) 1937 ?k) çfrcaf/r foKkiu (Prohibited Advertisement)
ç-10 i'kq Øwjrk fuokj.k vf/fu;e] 1960 ds vuqlkj] ^i'kq* 'kCn dk vFkZ gS
x) 1939 ?k) 1941
dksbZ Hkh thfor çk.kh] flok; bldsA
ç-2 IPR dk iwjk :i D;k gS\
d) i{kh (Birds) [k) tkuoj (Animals)
ç-3 PCI dh LFkkiuk fdl o"kZ gqbZ Fkh\
x) ekuo (Human Beings) ?k)mijksDr esa ls dksbZ ugha
d) 1919 [k) 1948 ç-11 tSo fpfdRlk dpjk çca/u fu;e (Biomedical Waste
x) 1949 ?k) 1942 Management Rules) dc vfLrRo esa vk, Fks\
ç-4 dkuwu cukus ds midj.k (Instruments of Legislation) D;k gSa\ ç-12 fo"k (Poison) vf/fu;e (Act) dc vfLrRo esa vk;k Fkk\
d) vf/fu;e (Act) [k) /kjk (Section) ç-13 nokvksa dh •qnjk dher (Retail Price) dh x.kuk esa ED dk D;k
x) vkns'k (Orders) ?k) mijksDr lHkh vFkZ gS\
ç-5 PCI dks gj fdrus o"kks± esa iquxZfBr fd;k tkrk gS\** d) mRikn 'kqYd (Excise Duty)
d) 1 o"kZ [k) 2 o"kZ [k) NwV çkIr 'kqYd (Exempted Duty)
x) 4 o"kZ ?k) 5 o"kZ x) vfrfjDr 'kqYd (Extra Duty)
ç-6 nok ds thoudky (Life Period) ds fy, vuqlwph (Schedule) ?k) vkikrdkyhu 'kqYd (Emergency Duty)
D;k gS\ ç-14 nokvksa dh dher fu;a=k.k vkns'k (Drugs Prices Control
d) vuqlwph Q [k) vuqlwph P Order) fdl ij ykxw gksrk gS\
x) vuqlwph R ?k) vuqlwph S d) vk;qoZsfnd nok,¡ (Ayurveda Medicines)
ç-7 u'khyh nokvksa ds mnkgj.k (Examples of Narcotic Drugs) b) ;wukuh nok,¡ (Unani Medicines)
d) viQhe (Opium) [k) dksdk (Coca) c) gksE;ksiSfFkd nok,¡ (Homoeopathic Medicines)
x) Hkkax (Hemp) ?k) mijksDr lHkh d) ,yksiSfFkd nok,¡ (Allopathic Medicines)

(5) ER20-26T (6) ER20-26T

ç-15 iQkeZslh dk vkpkj lafgrk (Code of Ethics of Pharmacy) fdlds }kjk iz-26 ljdkjh fo'ys"kdksa dh Hkwfedk vkSj ftEesnkfj;ksa dh O;k[;k djsaA
fodflr fd;k x;k gS\ iz-27 fo"kkDr inkFkks± vf/fu;e] 1919 ds rgr naM ij laf{kIr uksV fy•saA
d) PCI b) SPC iz-28 FSSAI ds dk;ks± ds ckjs esa foLrkj ls crk,aA
c) MCI d) DCGI iz-29 lhfyax ewY; vkSj cktkj ewY; dks ifjHkkf"kr djsaA
ç-16 ICMR dk iwjk :i D;k gS\ iz-30 uSnkfud ijh{k.kksa dh cqfu;knh vo/kj.kk ds ckjs esa le>k,aA
ç-17 esfMdy VfeZus'ku vkWiQ çsxusalh ,DV (Medical Termination of iz-31 miHkksDrk laj{k.k vf/fu;e ij laf{kIr uksV fy•saA
Pregnancy Act) fdl o"kZ ikl gqvk Fkk\ Hkkx & x
d) 1965 b) 1971 uksV%& y?kq mÙkjh; ç'uA 7 esa ls fdUgha 6 ç'uksa dks gy dhft,A
c) 1947 d) 1945 (6x5=30)
ç-18 CDSCO dk eq[;ky; (Headquarter) dgk¡ fLFkr gS\ iz-32 MªXl vkSj eSftd jsesMht (vokaNuh; foKkiu) vf/fu;e] 1954 ds
d) eqacbZ b) dksydkrk mís'; dk foLrkj ls o.kZu djsaA
c) psUubZ d) fnYyh iz-33 MªXl VsfDudy ,Mokbtjh cksMZ ds drZO; vkSj dk;Z D;k gSa\
ç-19 CDSCO ds fdrus {ks=kh; dk;kZy; (Zonal Offices) gSa\ iz-34 jkT; iQkeZslh dkmafly vkSj la;qDr jkT; iQkeZslh dkmafly ds dk;ks± vkSj
d) 6 b) 2 lajpuk dk foLrkj ls o.kZu djsaA
c) 4 d) 8 iz-35 iathÑr fpfdRlk fpfdRldksa }kjk xHkZikr ij laf{kIr uksV fy•saA
ç-20 Hkkjr dk nok fu;ked fudk; (Drug Regulatory Body) D;k gS\ iz-36 nok fodkl çfØ;k esa 'kkfey dneksa ds ckjs esa la{ksi esa le>k,aA
Hkkx & [k iz-37 u'ksM+h vkSj ekufld inkFkks± vf/fu;e ds rgr vijk/ vkSj naM dk
uksV%& oLrqfu"B ç'uA 11 esa ls 10 iz'uksa dks gy dhft,A (10x3=30) o.kZu djsaA
iz-21 Hkkjr ds i'kq dY;k.k cksMZ ds dk;Z D;k gSa\ iz-38 fuEufyf•r esa ls nks ij laf{kIr uksV fy•sa%
iz-22 MªXl vkSj dkWLesfVDl vf/fu;e 1948 ds vuqlkj vuqlwph lh] th vkSj (d) çfrcaf/r ykblsal
,p dh Hkwfedk dk fooj.k nsaA ([k) vko';d nokvksa dh jk"Vªh; lwph
iz-23 tSfod uSfrdrk ds fl¼karksa dh O;k[;k djsaA (x) tSo fpfdRlk dpjk
iz-24 mu nokb;ksa vkSj lkSan;Z çlk/uksa dh Jsf.k;ksa ds ckjs esa crk,a ftUgsa vk;kr
djus ls çfrcaf/r fd;k x;k gSA
iz-25 ykblsaflax çkf/dj.k ij laf{kIr uksV fy•saA

(7) ER20-26T (1820) (8) ER20-26T